Canertinib Uses, Dosage, Side Effects and more
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
| Attribute | Details |
|---|---|
| Trade Name | Canertinib |
| Generic | Canertinib |
| Canertinib Other Names | Canertinib |
| Type | |
| Formula | C24H25ClFN5O3 |
| Weight | Average: 485.938 Monoisotopic: 485.162995603 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in breast cancer and lung cancer.
How Canertinib works
CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.
